TIK seminar: Proposals for new incentives and reward models for stimulating antibiotics innovation

Jens Plahte, Senior Advisor at the International Department at the Norwegian Institute of Public Health (Folkehelseinstituttet) and also a former Research Fellow at the TIK-Centre, will provide a brief introduction to the problem of antibiotic resistance and explain the challenges encountered in antibiotics innovation.

Jens Plahte

Resistant to antibiotics

Dangerous bacteria are becoming resistant to antibiotics faster than new antibiotics are being developed to stop them. Since the late 1980's there has been a lack of innovation of novel antibiotics.

Fewer investors

For instance, in 1980, there were more than 25 pharmaceutical companies with active antibacterial drug discovery programs; today only four pharmaceutical companies invest in antibiotic-related research and development.

National & international initiatives

Recently, several national and international initiatives have been set up to address the issue, most notably the UK Review on Antimicrobial Resistance (the AMR Review), which has already issued several reports on different aspects of the antimicrobial resistance challenge.

About the lecturer

Jens Plahte MA PhD is trained in Development Geography and Innovation Studies, and is an expert on pharmaceutical policies in a global health perspective. He works as a Senior Advisor at the Department of International Public Health at the Norwegian Institute of Public Health. He was previously affiliated with the Norwegian Biotechnology Advisory Board and the Centre for Technology, Innovation and Culture at the University of Oslo. He has also worked in education and as an independent consultant.

Published Apr. 4, 2016 11:57 AM - Last modified Oct. 27, 2017 1:08 PM